The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial
Authors:
- Pär HallbergPHPär Hallberg
- Julia KarlssonJKJulia Karlsson
- Lisa KurlandLKLisa Kurland
- Lars LindLLLars Lind
- Thomas KahanTKThomas Kahan
- Karin MalmqvistKMKarin Malmqvist
- K. Peter ÖhmanKÖK. Peter Öhman
- Fredrik NyströmFNFredrik Nyström
- Håkan MelhusHMHåkan Melhus
- 1 October 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 20 (10) , 2089-2093
Abstract
The cytochrome P450 CYP2C9 enzyme (CYP2C9) metabolizes many clinically important drugs, for example, phenytoin, warfarin and the angiotensin II type 1 (AT1) receptor antagonists, losartan and irbesartan. Single nucleotide polymorphisms in the CYP2C9 gene result in the expression of three important variants, CYP2C9*1 (wild-type), CYP2C9*2 and CYP2C9*3, the last two exhibiting reduced catalytic activity compared with the wild-type. The CYP2C9 genotype is known to determine sensitivity to and dose requirements for both warfarin and phenytoin, and also the rate of metabolism of losartan. However, its influence on clinical response to treatment with the AT1 receptor antagonist, irbesartan, has not been investigated. To determine whether the CYP2C9 genotype influences the blood pressure-decreasing response to antihypertensive treatment with irbesartan. One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the β1-adrenergic receptor blocker, atenolol (n = 53). Blood pressure was measured before and after 12 weeks of treatment. CYP2C9 genotyping was performed using solid-phase minisequencing. The diastolic blood pressure (DBP) response differed in relation to the CYP2C9 genotype in patients given irbesartan: the reduction in patients with genotype CYP2C9*1/ CYP2C9*1 (n = 33) was 7.5% and that with CYP2C9*1/ CYP2C9*2 (n = 12) was 14.4% (P = 0.036). A similar trend was seen for systolic blood pressure. In contrast, no relation was seen between the CYP2C9 genotype and blood pressure response to atenolol, a drug not metabolized via CYP2C9. The CYP2C9 genotype seems to predict the DBP response to irbesartan, but not to atenolol, in patients with essential hypertension.Keywords
This publication has 15 references indexed in Scilit:
- Severe phenytoin intoxication in a subject homozygous for CYP2C9*3Clinical Pharmacology & Therapeutics, 2001
- Clinical relevance of genetic polymorphisms in the human CYP2C subfamilyBritish Journal of Clinical Pharmacology, 2001
- The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirementPharmacogenetics, 2001
- In vitro inhibition screening of human hepatic P 450 enzymes by five angiotensin-II receptor antagonistsEuropean Journal of Clinical Pharmacology, 2000
- Quantitative Analysis of Human DNA Sequences by PCR and Solid-Phase MinisequencingMolecular Biotechnology, 2000
- From gels to chips: ?Minisequencing? primer extension for analysis of point mutations and single nucleotide polymorphismsHuman Mutation, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Genetic analysis of the human cytochrome P450 CYP2C9 locusPharmacogenetics, 1996
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics, 1994